ASN
IOVA icon

Advisory Services Network’s Iovance Biotherapeutics IOVA Stock Holding History

Advisory Services Network’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,449
Closed -$29.7K – 3419
2026
Q1 		$29.7K Buy
+8,449
New +$27K ﹤0.01% 2959
2025
Q4 		– Sell
-10,000
Closed -$21.7K – 3053
2025
Q3 		$21.7K Buy
+10,000
New +$23.6K ﹤0.01% 2915
2022
Q2 		– Sell
-6,425
Closed -$107K – 1436
2022
Q1 		$107K Buy
+6,425
New +$99.4K ﹤0.01% 1397
2020
Q4 		– Sell
-100
Closed -$3K – 3490
2020
Q3 		$3K Buy
+100
New +$3.07K ﹤0.01% 2960

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Advisory Services Network's IOVA Position: Q2 2026 in Review

Advisory Services Network sold out of Iovance Biotherapeutics (IOVA) in Q2 2026, closing a stake of 8,449 shares — an estimated $29.7K sold.

Advisory Services Network first reported a position in IOVA in Q3 2020 and held it in 4 quarters. The position peaked at $107K in Q1 2022. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Advisory Services Network reported no remaining Iovance Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Advisory Services Network sold 8,449 Iovance Biotherapeutics shares in Q2 2026, an estimated $29.7K.
  • Advisory Services Network first reported a position in Iovance Biotherapeutics in Q3 2020 and held it in 4 quarters.
  • Advisory Services Network's Iovance Biotherapeutics position peaked at $107K in Q1 2022.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.